Fulcrum Therapeutics (NASDAQ:FULC) Price Target Increased to $6.00 by Analysts at The Goldman Sachs Group

Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) had its target price boosted by stock analysts at The Goldman Sachs Group from $5.00 to $6.00 in a report released on Thursday, Benzinga reports. The firm presently has a “neutral” rating on the stock. The Goldman Sachs Group’s price objective would indicate a potential downside of 13.67% […]

Related Keywords

United States ,China , ,Fulcrum Therapeutics Inc ,Goldman Sachs Group ,Nasdaq ,China Universal Asset Management Co ,Fulcrum Therapeutics Company Profile ,Citigroup Inc ,Fulcrum Therapeutics ,Get Free Report ,Therapeutics Stock Down ,Universal Asset Management ,Fulcrum Therapeutics Daily ,Nasdaq Fulc ,Fulc ,Medical ,Boost Price Target ,The Goldman Sachs Group Inc ,